Abstract: New galenic formulations with programmed release, to be administered by the oral route, containing as the active ingredient a drug selected from the non steroidal antiinflammatory, bronchodilator, vasodilator, cardiovascular and muscle relaxant drugs.

Abstract: A galenic formulations are disclosed with programmed release, to be administered orally containing as the active ingredient a compound having antiphlogistic, analgesic and antipyretic activity like, for instance, an arylacetic or an arylpropionic acid, and pharmaceutically acceptable salts thereof. In these new formulations, a portion of the active ingredient is released in a short time, so that the drug can quickly develop its therapeutic action and reach the necessary hematic levels, while the remaining portion of the active constituent is released in a longer interval of time so as to allow therapeutic coverage until subsequent administration. The therapeutic coverage can even last twenty-four hours. Thus, the new galenic formulations object of the present invention are suitable for administration one a day.

Abstract: New rifamicyn derivatives of the following general formula ##STR1## wherein: A may be the structure ##STR2## --x-- is a chemical bond or nil; R is hydrogen or acetylR.sub.1 and R.sub.2 independently represent hydrogen, (C.sub.1-4) alkyl, benzyloxy, mono- and di-(C.sub.1-3)alkylamino- (C.sub.1-4)alkyl, (C.sub.1-3)alkoxy- (C.sub.1-4)alkyl, hydroxymethyl, hydroxy-(C.sub.2-4)-alkyl, nitro or R.sub.1 and R.sub.2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups; R.sub.3 is a hydrogen atom or nil;with the proviso that, when A is A.sub.1, --x-- is nil and R.sub.3 is a hydrogen atom; with the further proviso that, when A is A.sub.2, --x-- is a chemical bond and R.sub.3 is nil.The compounds possess antibacterial utility.

Abstract: 8-amino and 8-iminorifamycins S and SV are prepared by reacting 8-methoxyrifamycin S with ammonia in an inert polar and hydrophillic solvent, converting the 8-iminorifamycin S into 8 aminorifamycin S by reaction with ammonium hydroxide in a mixture of chloroform and methanol and, if so desired, reducing the S forms to SV forms by reduction.

Abstract: New compounds being derivatives of 3-carboxyrifamycin S and SV are prepared by oxidation of cyanohydrin of 3-formylrifamycin S to 3-(cyanocarbonyl)rifamycin S, condensation with a compound of formula HR (an alcohol, an amine or an substituted hydrazine) and, optionally, reduction of the derivative of 3-carboxyrifamycin S so obtained to the corresponding SV form. Alternatively 3-(cyanocarbonyl)rifamycin S may be converted to the SV form before condensing with the compound HR.

Abstract: A process is disclosed for the preparation of 3 iodo-3 bromorifamycin S which consists in reacting rifamycin S with at least 2 equivalents of the corresponding halogen in the presence of at least one mole of pyridine for each equivalent of halogen. The reaction is carried out in inert, polar, hydrofillic solvents at a temperature not above the room temperature. The yields are very high and the products obtained have a high degree of purity.